针对慢性HBV感染治疗性疫苗的新方法
研究构建基于修饰性细胞穿透HBV衣壳的新型疫苗平台,负载PreS1PreS2抗原,小鼠免疫实验显示可诱导特异性细胞免疫破坏HBV阳性细胞并产生中和抗体,口服或经皮接种亦可诱导CTL和B细胞应答。
要点
- 新型疫苗平台基于融合TLM肽的HBV核心单体组装成的细胞穿透衣壳。
- 小鼠免疫可诱导特异性细胞免疫、破坏HBV阳性细胞并产生HBV中和抗体。
- 衣壳膜穿透性支持口服或经皮无针接种并诱导CTL及B细胞应答。
核心结论
- 基于HBV衣壳的细胞穿透抗原载体负载HBV抗原后,有能力诱导体液和细胞免疫应答。
- 该疫苗平台的细胞穿透性使抗原跨越多层细胞,可能允许口服或经皮免疫。
研究设计与样本
- 研究采用新型疫苗平台,将膜穿透性TLM肽融合至HBV核心单体以组装细胞穿透衣壳。
- 在衣壳表面 spike tip 域插入Strep-tagIII,可以灵活加载融合链霉亲和素的抗原。
- 本研究以融合单体链霉亲和素的HBV表面抗原来源PreS1PreS2域作为货物抗原。
- 采用表面等离子共振光谱、电子显微镜和密度梯度离心表征抗原与衣壳的结合。
- 对免疫小鼠进行共聚焦免疫荧光显微镜和活体成像,并开展小鼠免疫实验。
主要发现
- 抗原与衣壳的结合经表面等离子共振光谱、电子显微镜和密度梯度离心表征。
- 共聚焦免疫荧光显微镜和免疫小鼠活体成像显示载货载体具有膜穿透性,抗原分布于整个生物体。
- 小鼠免疫实验显示稳健诱导特异性细胞免疫应答,导致HBV阳性细胞被破坏并诱导HBV特异性中和抗体。
- 口服或经皮接种后诱导HBV特异性CTL应答和HBV特异性B细胞应答,证明载体膜穿透性支持无针应用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There are currently about 257 million people suffering from chronic HBV infection worldwide. In many cases, an insufficient Tcell response is causative for establishment of a chronic infection. To ensure a robust cellular immune response and induction of neutralizing antibodies a novel vaccine platform based on modified cell-permeable HBV capsids was utilized. Cell permeability was achieved by fusion of the membrane-permeable TLM-peptide to HBV core monomers, assembling the capsids. Insertion of a Strep-tagIII into the spike tip domain that protrudes from the capsid surface enables flexible loading with antigens that are fused to streptavidin. In this study, HBV surface antigen-derived PreS1PreS2 domain, fused to monomeric streptavidin, served as cargo antigen. Binding between antigen and capsids was characterized by surface plasmon resonance spectroscopy, electron microscopy and density gradient centrifugation. Confocal immunofluorescence microscopy and in vivo imaging of immunized mice demonstrated membrane permeability of cargo-loaded carriers and spread of antigen over the whole organism. Immunization experiments of mice revealed a robust induction of a specific cellular immune response, leading to destruction of HBV-positive cells and induction of HBV-specific neutralizing antibodies. Membrane permeability of these carriers allows needle-free application of antigen-loaded capsids as evidenced by induction of an HBV-specific CTL response and HBV-specific B cell response after oral or transdermal vaccination. These data indicate that cell-permeable antigen carriers, based on HBV capsids and loaded with HBV antigen, have the capacity to induce a cellular and a neutralizing humoral immune response. In addition, cell permeability of the vaccine platform enables antigen transfer across several cell layers, that could allow oral or transdermal immunization.
引用
- Zahn T, Akhras S, Spengler C, et al. A new approach for therapeutic vaccination against chronic HBV infections. Vaccine. 2020. PMID: 32113806. doi:10.1016/j.vaccine.2020.02.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。